Shu-ying Yu1, Xia-yan Zhang2, Xiao-rong Wang2, Dong-min Xu2, Lu Chen3, Li-hui Zhang3, San-hua Fang2, Yun-bi Lu2, Wei-ping Zhang2, Er-qing Wei2. 1. 1] Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China [2] Department of Pharmacology, Hangzhou Pediatric Hospital, Hangzhou 310004, China. 2. Department of Pharmacology, School of Medicine, Zhejiang University, Hangzhou 310058, China. 3. Hangzhou Key Laboratory of Neurobiology and Department of Pharmacology, School of Basic Medicine, Hangzhou Normal University, Hangzhou 310036, China.
Abstract
AIM: To investigate the roles of cysteinyl leukotriene receptors CysLT1R and CysLT2R in leukotriene D4 (LTD4)-induced activation of microglial cells in vitro. METHODS: Mouse microglial cell line BV2 was transfected with pcDNA3.1(+)-hCysLT1R or pcDNA3.1(+)-hCysLT2R. The expression of relevant mRNAs and proteins in the cells was detected using RT-PCR and Western blotting, respectively. Phagocytosis was determined with flow cytometry analysis. The release of interleukin-1β (IL-1β) from the cells was measured using an ELISA assay. RESULTS: The expression of CysLT1R or CysLT2R was considerably increased in the transfected BV2 cells, and the receptors were mainly distributed in the plasma membrane and cytosol. Treatment of the cells expressing CysLT1R or CysLT2R with CysLT receptor agonist LTD4 (0.1-100 nmol/L) concentration-dependently enhanced the phagocytosis, and increased mRNA expression and release of IL-1β. Moreover, the responses of hCysLT1R-BV2 cells to LTD4 were significantly larger than those of hCysLT2R-BV2 or WT-BV2 cells. Pretreatment of hCysLT1R-BV2 cells with the selective CysLT1R antagonist montelukast (1 μmol/L) significantly blocked LTD4-induced phagocytosis as well as the mRNA expression and release of IL-1β, whereas the selective CysLT2R antagonist HAMI 3379 (1 μmol/L) had no such effects. CONCLUSION: CysLT1R mediates LTD4-induced activation of BV2 cells, suggesting that CysLT1R antagonists may exert anti-inflammatory activity in brain diseases.
AIM: To investigate the roles of cysteinyl leukotriene receptors CysLT1R and CysLT2R in leukotriene D4 (LTD4)-induced activation of microglial cells in vitro. METHODS:Mouse microglial cell line BV2 was transfected with pcDNA3.1(+)-hCysLT1R or pcDNA3.1(+)-hCysLT2R. The expression of relevant mRNAs and proteins in the cells was detected using RT-PCR and Western blotting, respectively. Phagocytosis was determined with flow cytometry analysis. The release of interleukin-1β (IL-1β) from the cells was measured using an ELISA assay. RESULTS: The expression of CysLT1R or CysLT2R was considerably increased in the transfected BV2 cells, and the receptors were mainly distributed in the plasma membrane and cytosol. Treatment of the cells expressing CysLT1R or CysLT2R with CysLT receptor agonist LTD4 (0.1-100 nmol/L) concentration-dependently enhanced the phagocytosis, and increased mRNA expression and release of IL-1β. Moreover, the responses of hCysLT1R-BV2 cells to LTD4 were significantly larger than those of hCysLT2R-BV2 or WT-BV2 cells. Pretreatment of hCysLT1R-BV2 cells with the selective CysLT1R antagonist montelukast (1 μmol/L) significantly blocked LTD4-induced phagocytosis as well as the mRNA expression and release of IL-1β, whereas the selective CysLT2R antagonist HAMI 3379 (1 μmol/L) had no such effects. CONCLUSION:CysLT1R mediates LTD4-induced activation of BV2 cells, suggesting that CysLT1R antagonists may exert anti-inflammatory activity in brain diseases.
Authors: Dorien M Schrijvers; Wim Martinet; Guido R Y De Meyer; Luc Andries; Arnold G Herman; Mark M Kockx Journal: J Immunol Methods Date: 2004-04 Impact factor: 2.303
Authors: Y Hui; G Yang; H Galczenski; D J Figueroa; C P Austin; N G Copeland; D J Gilbert; N A Jenkins; C D Funk Journal: J Biol Chem Date: 2001-10-08 Impact factor: 5.157
Authors: Charles Brink; Sven-Erik Dahlén; Jeffrey Drazen; Jilly F Evans; Douglas W P Hay; Simonetta Nicosia; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo Journal: Pharmacol Rev Date: 2003-03 Impact factor: 25.468
Authors: Søren Lund; Peter Porzgen; Anne Louise Mortensen; Henrik Hasseldam; Donna Bozyczko-Coyne; Siegfried Morath; Thomas Hartung; Marina Bianchi; Pietro Ghezzi; Malika Bsibsi; Sipke Dijkstra; Marcel Leist Journal: J Neurochem Date: 2005-03 Impact factor: 5.372
Authors: E Porreca; P Conti; C Feliciani; C Di Febbo; M Reale; G Mincione; M Neri; P Amerio; F Cuccurullo Journal: Atherosclerosis Date: 1995-06 Impact factor: 5.162
Authors: Paolo Gelosa; Francesca Colazzo; Elena Tremoli; Luigi Sironi; Laura Castiglioni Journal: Mediators Inflamm Date: 2017-05-10 Impact factor: 4.711
Authors: J Michael; M S Unger; R Poupardin; P Schernthaner; H Mrowetz; J Attems; L Aigner Journal: Acta Neuropathol Commun Date: 2020-08-08 Impact factor: 7.801
Authors: Katharina Strempfl; Michael S Unger; Stefanie Flunkert; Andrea Trost; Herbert A Reitsamer; Birgit Hutter-Paier; Ludwig Aigner Journal: Biomolecules Date: 2022-02-23